Trogarzo (Ibalizumab-uiyk) for HIV

Overview
Trogarzo is a prescription medication approved by the Food and Drug Administration (FDA) to treat HIV-1 in adults who have already tried several different HIV treatments. Trogarzo may be prescribed in cases of multidrug-resistant HIV-1 or when the current antiretroviral regimen is ineffective. Trogarzo is also known by its drug name, Ibalizumab-uiyk. Trogarzo is the first member in a new class of drugs called post-attachment inhibitors. As a genetically engineered protein, Trogarzo is also considered a biologic drug. Trogarzo believed to work by preventing HIV from entering CD4 cells.

How do I take it?
Trogarzo is administered once every two weeks by intravenous infusion. Trogarzo is available as a single-dose vial.

Side effects
The FDA-approved label for Trogarzo lists common side effects including dizziness, rash, nausea, and diarrhea. Rare but serious side effects listed for Trogarzo include immune reconstitution inflammatory syndrome.

For more details about this treatment, visit:

Trogarzo.com – Theratechnologies